According to REACH Market Research, dermatologists agree that Frontal Fibrosing Alopecia (FFA) is generally more difficult to treat, and less likely to have an optimal response to treatment than Alopecia Areata [...]
First-to-market Regeneron/Sanofi's Dupixent (dupilumab) sees strong uptake in Eosinophilic Esophagitis (EoE) since its May 2022 FDA approval, according to findings from REACH Market Research. NEWTON, Mass., Feb. 21, 2023 /PRNewswire/ -- Despite being recognized [...]
A study with 50 U.S. hematologists reveals that approximately one-third have already prescribed Adakveo or Oxbryta Newton, MA., September 30, 2020 — Sickle cell disease (SCD) is a chronic, [...]
Young adulthood is one of the most exciting times in life. It is full of new experiences, challenges, freedoms, and responsibilities. Young adults living with a chronic medical condition have [...]
In the midst of the COVID-19 pandemic, sickle cell disease patients, their caregivers, and their physicians are challenged to find ways to avoid hospital visits, manage acute pain crises at [...]
Investment in R&D is set to deliver much-needed, potentially disease-modifying therapies for people with sickle cell disease (SCD), especially those with severe disease. Severe disease is characterized by frequent [...]
The last six months have delivered a wave of clinical, commercial, and regulatory developments regarding the treatment of sickle cell disease (SCD). Indeed, the U.S. launch of two new [...]